| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 07/03/2025 | 22:29 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 03/03/2025 | 22:30 | GlobeNewswire Inc. | Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 27/02/2025 | 14:00 | GlobeNewswire Inc. | 2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 25/02/2025 | 23:03 | Business Wire | Teva et Medincell annoncent l'acceptation par la FDA du dossier de demande d’extension d’indication de UZEDY® (rispéridone) pour le traitement de patients atteints de trouble bipolaire de type I | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 25/02/2025 | 23:03 | Business Wire | Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 25/02/2025 | 22:00 | GlobeNewswire Inc. | Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 22/02/2025 | 08:20 | GlobeNewswire Inc. | Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 21/02/2025 | 12:00 | GlobeNewswire Inc. | Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 18/02/2025 | 22:30 | GlobeNewswire Inc. | Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 18/02/2025 | 12:00 | GlobeNewswire Inc. | Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 18/02/2025 | 12:00 | GlobeNewswire Inc. | Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 29/01/2025 | 13:00 | GlobeNewswire Inc. | Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 27/01/2025 | 12:00 | GlobeNewswire Inc. | Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 27/01/2025 | 12:00 | GlobeNewswire Inc. | Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 13/01/2025 | 07:00 | GlobeNewswire Inc. | Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 10/01/2025 | 14:30 | GlobeNewswire Inc. | Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 23/12/2024 | 22:30 | GlobeNewswire Inc. | Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 20/12/2024 | 22:30 | GlobeNewswire Inc. | Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 17/12/2024 | 13:30 | GlobeNewswire Inc. | Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 11/12/2024 | 14:00 | GlobeNewswire Inc. | Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 06/12/2024 | 00:00 | GlobeNewswire Inc. | Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 04/12/2024 | 08:00 | GlobeNewswire Inc. | Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 26/11/2024 | 00:00 | GlobeNewswire Inc. | Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 20/11/2024 | 17:39 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 08/11/2024 | 22:30 | GlobeNewswire Inc. | Teva to Present at the Jefferies London Healthcare Conference | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 06/11/2024 | 22:06 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 06/11/2024 | 13:00 | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 06/11/2024 | 13:00 | GlobeNewswire Inc. | Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 06/11/2024 | 12:12 | IH Market News | U.S. Index Futures Surge on Trump Victory Prospects; Commodities Slide Amid Dollar Strength | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
| 01/11/2024 | 20:05 | GlobeNewswire Inc. | Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
